These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19735356)

  • 21. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erectile dysfunction.
    Katz A; Katz A
    CMAJ; 2010 Mar; 182(4):381-2. PubMed ID: 20142374
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
    Kamenov ZA
    J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
    Sanna F; Succu S; Boi A; Melis MR; Argiolas A
    J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study.
    Miner MM; Barnes A; Janning S
    J Sex Med; 2010 May; 7(5):1937-47. PubMed ID: 20202105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.
    Hackett GI
    Clin Cornerstone; 2005; 7(1):57-65. PubMed ID: 16156424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications.
    Eardley I; Lee JC; Shabsigh R; Dean J; Maggi M; Neuser D; Norenberg C
    J Sex Med; 2010 Jan; 7(1 Pt 1):244-55. PubMed ID: 20104672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
    Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
    BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
    Herlemann A; Gratzke C; Andersson KE; Sievert KD
    Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
    Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.